A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies

Leukemia

Volumn 32, Issue 2, 2018, Pages 547-549

  Casey, E ^a   Bournazos, S ^b   Mo, G ^a   Mondello, P ^a   Tan, K S ^a   Ravetch, J V ^b   Scheinberg, D A ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC MONOCLONAL ANTIBODY; FC RECEPTOR; FC RECEPTOR GAMMA; OBINUTUZUMAB; RITUXIMAB; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ANTIBODY RESPONSE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNE RESPONSE; LETTER; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; ANIMAL; IMMUNOLOGY; MOUSE; NEOPLASM; NEUTROPHIL;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; MICE; NEOPLASMS; NEUTROPHILS; RECEPTORS, IGG;

EID: 85042329552     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.293     Document Type: Letter

References (10)

1. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene. Blood 2002; 99: 754-758.
2. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947.
3. Clark MR. IgG effector mechanisms. Chem Immunol 1996; 65: 88-110.
4. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005; 310: 1510-1512.
5. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotech 2014; 32: 40-51.
6. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcRIV: A novel FcR with distinct IgG subclass specificity. Immunity 2005; 23: 41-51.
7. Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fc receptor structural and functional diversity. Proc Natl Acad Sci USA 2012; 109: 6181-6186.
8. Bournazos S, DiLillo DJ, Ravetch JV. In: Daeron M, Nimmerjahn F (eds). Fc Receptors. Springer International Publishing: Switzerland, 2014, pp 237-248.
9. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-1110.
10. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotypespecific engagement of Fc receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 2006; 203: 743-753.